VRPX
Virpax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -91.8%
- EBIT
- +23.0%
- EPS
- +55.4%
- Free cash flow
- -69.6%
- Operating cash flow
- -69.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +18.6%
- EBIT
- +23.0%
- Net income
- +20.6%
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2024